-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Assumes Bolt Biotherapeutics at Buy, Announces Price Target of $7

Benzinga·10/20/2025 10:44:48
Listen to the news
HC Wainwright & Co. analyst Robert Burns assumes Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Price Target of $7.